Tag: Pharma M&A
-
Why AstraZeneca Investors Rejected a $400 Billion BMS Megadeal
Reports of a potential $400 billion AstraZeneca–Bristol Myers Squibb combination triggered a sharp market backlash and renewed questions about the value of Big Pharma megamergers.
-
AstraZeneca and Bristol Myers Squibb Explore a $400 Billion Pharma Megadeal
AstraZeneca and Bristol Myers Squibb have reportedly explored a potential $400 billion merger. While no deal has been announced, the discussions highlight how U.S. expansion, portfolio diversification and long-term growth are reshaping strategic priorities across the global pharmaceutical industry.